Corona Remedies于12月8日启动IPO，通过股票出售筹集了65.5亿卢比，上市时间定于12月15日。 Corona Remedies' IPO launched Dec. 8, raising ₹655 crore via share sale, with listing set for Dec. 15.

Corona Remedies 于 2025 年 12 月 8 日首次公开募股，股票价格在 ₹1,008 至 ₹1,062 之间，通过现有股东的出售要约筹集了 ₹65.37 亿卢比，这意味着公司将不会获得任何收益。 Corona Remedies' IPO opened on December 8, 2025, with shares priced between ₹1,008 and ₹1,062, raising ₹655.37 crore through an offer for sale by existing shareholders, meaning the company won’t receive any proceeds. 该议题由JM Finance、IIFL Capital和Kotak Mahindra Capital管理,于12月10日结束,定于12月15日列出。 The issue, managed by JM Financial, IIFL Capital, and Kotak Mahindra Capital, closed on December 10 and is set to list on December 15. 隐含着投资者强烈兴趣的信号是,灰色市场溢价290,表明可能上市价格比上限价格幅度高出27%。 Strong investor interest was signaled by a grey market premium of ₹290, suggesting a potential listing price 27% above the upper price band. 零售投资者表现出巨大的需求,而合格的机构购买者尚未出价。 Retail investors showed significant demand, while qualified institutional buyers had not yet bid. 以艾哈迈达巴德为基地的药房公司专门从事妇女健康、心血管疾病护理、疼痛治疗和泌尿科,它报告了强劲的经济和增长,2022年至2025年,国内销售额占CAGR的16.77%,超过了行业平均水平。 The Ahmedabad-based pharma firm, specializing in women’s health, cardio-diabeto care, pain management, and urology, reported strong financials and growth, with a 16.77% CAGR in domestic sales from 2022 to 2025, outpacing the industry average. 分析师指出，基本面稳健，储备前景可期，尽管IPO已完全定价，且无新资金用于扩张。 Analysts note robust fundamentals and a promising pipeline, though the IPO is fully priced, with no fresh capital for expansion.